Palvella Therapeutics (PVLA) Total Non-Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Total Non-Current Liabilities data on file, last reported at $19.8 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $19.8 million, down 10.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.8 million (down 10.57% YoY), and the FY2025 annual result was $17.8 million, up 49.58% from the prior year.
• Total Non-Current Liabilities climbed to $19.8 million in Q1 2026 per PVLA's latest filing, from $17.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $67.6 million in Q4 2022 and troughed at $10.4 million in Q4 2023.
• A 5-year average of $25.2 million and a median of $17.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities sank 84.59% in 2023, then soared 49.58% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $67.6 million in 2022, then slumped by 84.59% to $10.4 million in 2023, then advanced by 14.27% to $11.9 million in 2024, then soared by 49.58% to $17.8 million in 2025, then gained by 11.24% to $19.8 million in 2026.
• Business Quant data shows PVLA's Total Non-Current Liabilities at $19.8 million in Q1 2026, $17.8 million in Q4 2025, and $16.0 million in Q3 2025.